Adrenocortical carcinoma natural history

Jump to: navigation, search

Adrenocortical carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenocortical carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

MRI

CT

Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation Therapy

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Adrenocortical carcinoma natural history On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenocortical carcinoma natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenocortical carcinoma natural history

CDC on Adrenocortical carcinoma natural history

Adrenocortical carcinoma natural history in the news

Blogs on Adrenocortical carcinoma natural history</small>

Hospitals Treating Adrenocortical carcinoma

Risk calculators and risk factors for Adrenocortical carcinoma natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Ahmad Al Maradni, M.D. [3]

Overview

Prognosis is generally poor, and the 5-year survival rate of patients with adrenocortical carcinoma stage I-III is approximately 30%. Complication may include metastasis, Conn syndrom and Cushing syndrom

Complications

The following are the complications of Adrenocortical carcinoma:

Prognosis

Adrenocortical carcinoma, generally, carries a poor prognosis.[1] The five-year disease-free survival rate for a complete resection of a stage I-III is approximately 30%.[1]

The most important prognostic factors are:

  • Age of the patient
  • Stage of the tumor
  • Mitotic activity
  • Venous invasion
  • Weight more than 50 Kg
  • Diameter more than 6.5 cm
  • Ki-67/MIB1 labeling index (antigen identified by monoclonal antibody Ki-67)

References

  1. 1.0 1.1 Allolio B, Fassnacht M (2006). "Clinical review: Adrenocortical carcinoma: clinical update.". J Clin Endocrinol Metab 91 (6): 2027-37. PMID 16551738. Free Full Text.

Linked-in.jpg